株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

免疫チェックポイント阻害剤の世界市場:将来展望

Global Immune Checkpoint Inhibitors Market Outlook 2022

発行 RNCOS E-Services Pvt. Ltd. 商品コード 606409
出版日 ページ情報 英文 60 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.36円で換算しております。
Back to Top
免疫チェックポイント阻害剤の世界市場:将来展望 Global Immune Checkpoint Inhibitors Market Outlook 2022
出版日: 2018年10月18日 ページ情報: 英文 60 Pages
概要

当レポートでは、世界の免疫チェックポイント阻害剤の市場について分析し、疾患・製品の概要や、主な市場促進・抑制要因、市場全体の動向見通し、製品クラス別・適応症別の詳細動向、昨今の資本取引・事業提携の動き、パイプライン製品の治験動向、主要企業のプロファイルなどを調査しております。

第1章 アナリストの見解

第2章 分析手法

第3章 免疫チェックポイント阻害剤:概要

第4章 市場のダイナミクス

  • 市場促進要因
  • 課題
  • 市場機会

第5章 市場の将来展望

第6章 世界の免疫チェックポイント阻害剤の売上高:製品クラス別

  • CTLA-4 (細胞傷害性Tリンパ球抗原4) 阻害剤
    • Yervoy (イピリムマブ)
  • PD-1 (プログラム細胞死-1)/PD-L1 (プログラム細胞死リガンド-1) 阻害剤
    • Tecentriq (アテゾリズマブ)
    • Bavencio (アベルマブ)
    • Imfinzi (デュルバルマブ)
    • Opdivo (ニボルマブ)
    • Keytruda (ペンブロリズマブ)

第7章 主な適応症における免疫チェックポイント阻害剤の用途

  • 頭部・頚部がん
  • 肺がん
  • 黒色腫
  • リンパ腫
  • 白血病
  • その他

第8章 市場の傾向と動静

第9章 免疫チェックポイント阻害剤市場における戦略的な事業協力・連携

第10章 免疫チェックポイント阻害剤のパイプライン製品の分析

第11章 主要企業の分析

  • Genentech, Inc. (Roche Groupの一員)
  • CureTech Ltd.
  • NewLink Genetics Corporation
  • Novartis AG
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • AstraZeneca Plc
  • Pfizer Inc
  • 小野薬品工業
  • EMD Serono, Inc.
目次

Given the wealth of potential targets to overcome tumor-induced immune suppression, many novel active immunotherapies are in clinical development across a range of solid tumor types. The most advanced in development are checkpoint inhibitors. These checkpoint inhibitors have dramatically altered the natural history of hard-to-treat cancers by producing substantial clinical benefits for certain tumor types and patients. Some of these checkpoints are called PD-1, PD-L1, and CTLA-4 receptors. They work by activating the body's immune system against antigens expressed on tumor cells. Drugs that target these checkpoints hold great promise and have generated a tremendous interest in further developing and exploring these strategies across the oncology disease spectrum.

According to the report "Global Immune Checkpoint Inhibitors Market Outlook 2022", the global immune checkpoint inhibitors market is anticipated to cross US$ 25 Billion by 2022. The report provides a detailed analysis of the global immune checkpoint inhibitors market. The report also provides the current and forecasted market for immune checkpoint inhibitors.

Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immune checkpoint inhibitors market. Moreover, the report provides the sales of commercialized immune checkpoint inhibitors.

The global immune checkpoint inhibitors market has been segmented on the basis of type of product into PD-1, PD-L1, and CTLA-4. According to the report, PD-1 segment was estimated to account for the largest share in 2016 due to entry of multiple pharmaceutical players in the PD-1 inhibitors market, increasing investments from various key pharmaceutical companies and active research with many pharmaceutical companies looking to launch there products.

On the basis of type of cancer, the immune checkpoint inhibitors market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immune checkpoint inhibitors market.

A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immune checkpoint inhibitors programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

The later part of the report discusses some of the prominent players in the global immune checkpoint inhibitors market. A brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immune checkpoint inhibitor is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.

Table of Contents

1. Analyst View

2. Research Methodology

3. Immune Checkpoint Inhibitors: Overview

4. Market Dynamics

  • 4.1 Drivers
    • 4.1.1 Increasing Cancer Incidences
    • 4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
    • 4.1.3 Growing Geriatric Population
    • 4.1.4 High Healthcare Spending in Developed Economies
    • 4.1.5 Strong Pipeline
    • 4.1.6 Increasing Efficacy in a Wide Variety of Indications
    • 4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products
  • 4.2 Challenges
    • 4.2.1 Increasing Number of Side-Effects Post Immunotherapy Treatments
    • 4.2.2 Sky-High Development Costs of Cancer Immunotherapies
    • 4.2.3 High Cost of Treatment
    • 4.2.4 Lack of Awareness
  • 4.3 Opportunities
    • 4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity
    • 4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival
    • 4.3.3 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies

5. Global Immune Checkpoint Inhibitors Market Outlook 2022

6. Global Immune Checkpoint Inhibitors Market, by Product Class

  • 6.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
    • 6.1.1 Yervoy (Ipilimumab)
  • 6.2 PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand
    • 6.2.1 Tecentriq (Atezolizumab)
    • 6.2.2 Bavencio (Avelumab)
    • 6.2.3 Imfinzi (Durvalumab)
    • 6.2.4 Opdivo (Nivolumab)
    • 6.2.5 Keytruda (Pembrolizumab)

7. Application of Immune Checkpoint Inhibitors in Major Indications

  • 7.1 Head & Neck Cancer
  • 7.2 Lung Cancer
  • 7.3 Melanoma
  • 7.4 Lymphoma
  • 7.5 Leukemia
  • 7.6 Others

8. Trends & Developments

  • 8.1 Lucrative Investment Trend
  • 8.2 Emergence of Targeted and Combination Therapies
  • 8.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
  • 8.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers

9. Strategic Collaborations & Alliances in the Immune Checkpoint Inhibitors Market

10. Pipeline Analysis of Immune Checkpoint Inhibitors

11. Key Players Analysis

  • 11.1 Genentech, Inc. (A Member of the Roche Group)
  • 11.2 CureTech Ltd.
  • 11.3 NewLink Genetics Corporation
  • 11.4 Novartis AG
  • 11.5 Bristol-Myers Squibb
  • 11.6 Merck & Co., Inc.
  • 11.7 AstraZeneca Plc
  • 11.8 Pfizer Inc
  • 11.9 Ono Pharmaceutical Co., Ltd.
  • 11.10 EMD Serono, Inc.

List of Figures:

  • Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
  • Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
  • Figure 4-3: Global - Population above 60 Years (Billion), 2015 & 2050
  • Figure 4-4: Expected Combination Regimen Launches in Oncology
  • Figure 5-1: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2016-2022
  • Figure 6-1: Global - Yervoy Market (Million US$), 2012-2018
  • Figure 6-2: Global - Tecentriq Market (Million US$), 2016 & 2017
  • Figure 6-3: Global - Bavencio Market (Million US$), 2017-2021
  • Figure 6-4: Global - Imfinzi Market (Million US$), 2017
  • Figure 6-5: Global - Opdivo Market (Million US$), 2014-2016
  • Figure 6-6: Global - Keytruda Market (Million US$), 2014-2016
  • Figure 7-1: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-2: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-3: Lung Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-4: Lung Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-5: Melanoma - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-6: Melanoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-7: Lymphoma - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-8: Lymphoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-9: Leukemia - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-10: Leukemia - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-11: Other Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-12: Other Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 8-1: Immuno-Oncology Funding by Product Type (Billion, US$), 2015-2016
  • Figure 8-2: Major Investors in Immuno-Oncology Market (2015-2016)
  • Figure 8-3: Bristol-Myers Squibb and Merck & Co. - Strategic Collaborations
  • Figure 10-1: Global - Immune Checkpoint Inhibitors Pipeline Analysis by Product Type (%), 2016
  • Figure 10-2: Global - Immune Checkpoint Inhibitors Pipeline Analysis by Phase (%), 2016
  • Figure 11-1: F. Hoffmann-La Roche AG - Sales by Business Segments (%), 2016
  • Figure 11-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Segments (%), 2016
  • Figure 11-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Geography (%), 2016
  • Figure 11-4: Novartis AG - Breakup of Sales by Business Segment (%), 2016
  • Figure 11-5: Novartis AG - Breakup of Pharmaceuticals Division Sales by Segment (%), 2016
  • Figure 11-6: Novartis AG - Breakup of Sales by Geography (%), 2016
  • Figure 11-7: Bristol Myers Squibb - Revenue by Business Segments (%), 2016
  • Figure 11-8: Bristol Myers Squibb - Revenue by Geography (%), 2016
  • Figure 11-9: Merck & Co., Inc. - Revenue by Business Segments (%), 2016
  • Figure 11-10: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segments (%), 2016
  • Figure 11-11: Merck & Co., Inc. - Revenue by Geography (%), 2016
  • Figure 11-12: AstraZeneca Plc - Revenue by Business Segments (%), 2016
  • Figure 11-13: AstraZeneca Plc - Revenue by Geography (%), 2016
  • Figure 11-14: Pfizer Inc - Revenue by Business Segments (%), 2016
  • Figure 11-15: Pfizer Inc - Revenue by Geography (%), 2016

List of Tables:

  • Table 4-1: Immune Checkpoint Inhibitors - Late Stage Research Pipeline
  • Table 6-1: Ongoing Trials for Yervoy
  • Table 6-2: Ongoing Trials for Opdivo
  • Table 6-3: Ongoing Trials for Keytruda
  • Table 7-1: Global - Oncology Incidence by Geography ('000), 2015 & 2020
  • Table 8-1: Selected Immuno-Oncology and Targeted Therapy Combinations
  • Table 9-1: Strategic Collaborations in the Immune Checkpoint Inhibitors Market
  • Table 10-1: Active Immune Checkpoint Inhibitors Programs
  • Table 10-2: Global - Immune Checkpoint Inhibitors Product Pipeline
  • Table 11-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2014-2016
  • Table 11-2: Genentech, Inc. - Commercialized Immune Checkpoint Inhibitors
  • Table 11-3: Genentech, Inc. - Product Pipeline
  • Table 11-4: CureTech Ltd. - Product Pipeline
  • Table 11-5: NewLink Genetics Corporation- Key Financials (Million US$), 2014-2016
  • Table 11-6: NewLink Genetics Corporation - Product Pipeline
  • Table 11-7: Novartis AG - Key Financials (Billion US$), 2014-2016
  • Table 11-8: Novartis AG - Product Pipeline
  • Table 11-9: Bristol Myers Squibb - Key Financials (Million US$), 2014-2016
  • Table 11-10: Bristol Myers Squibb - Commercialized Immune Checkpoint Inhibitors
  • Table 11-11: Bristol Myers Squibb - Product Pipeline
  • Table 11-12: Merck & Co., Inc. - Key Financials (Million US$), 2014-2016
  • Table 11-13: Merck & Co., Inc. - Commercialized Immune Checkpoint Inhibitors
  • Table 11-14: Merck & Co., Inc. - Product Pipeline
  • Table 11-15: AstraZeneca Plc - Key Financials (Million US$), 2014-2016
  • Table 11-16: AstraZeneca Plc - Commercialized Immune Checkpoint Inhibitors
  • Table 11-17: AstraZeneca Plc - Product Pipeline
  • Table 11-18: Pfizer Inc - Key Financials (Billion US$), 2014-2016
  • Table 11-19: Pfizer Inc - Commercialized Immune Checkpoint Inhibitors
  • Table 11-20: Pfizer Inc - Product Pipeline
  • Table 11-21: Ono Pharmaceutical Co., Ltd. - Key Financials (Million US$), FY2014-FY2016
  • Table 11-22: Ono Pharmaceutical Co., Ltd. - Commercialized Immune Checkpoint Inhibitors
  • Table 11-23: Ono Pharmaceutical Co., Ltd. - Product Pipeline
  • Table 11-24: EMD Serono, Inc. - Commercialized Immune Checkpoint Inhibitors
  • Table 11-25: EMD Serono, Inc. - Product Pipeline
Back to Top